Advertisement

Resistenzbestimmung für HIV-1 für Nukleosidanaloga durch In-vitro-Kultur und gleichzeitige Nukleinsäurensequenzierung

  • A. von Brunn
  • J. Eberle
  • U. Notheis
  • G. Auberger
  • F. Rommel
  • W. Schramm
  • L. Bader
  • L. Gürtler
Conference paper

Zusammenfassung

HIV hat drei Enzyme, die für eine therapeutische Intervention ausgenützt werden können: die reverse Transkriptase, die Proteinase und die Integrase. Während für die Testung der Inhibtion der Proteinase klinische Studien ab 1992/93 begonnen wurden, hat die Beeinflussung des HIV Wachstums durch Nukleosidanaloga durch die Hemmung der reversen Transskriptase ab 1986 zu ersten verwertbaren Ergebnissen geführt [1].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Mitsuya H, Broder S (1986) Inhibition of the in vitro infectivity and cytopathic effect of human T-Lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2’,3’-didesoxynucleosides. Proc Nat Acd Sci USA 83: 1911–1915CrossRefGoogle Scholar
  2. 2.
    Nakashima H, Matsui T, Harada S, Kobayashi N, Matsuda A, Ueda T, Yamamoto N (1986) Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 2’-azido-3’-desoxythymidine in vitro. Antimicrob Agents Chemother 30: 933–937PubMedGoogle Scholar
  3. 3.
    Moore RD, Hidalgo J, Sugland BW, Chaisson RE (1991) Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med 324: 1412–1416PubMedCrossRefGoogle Scholar
  4. 4.
    Larder BA, Darby G, Richman DD (1989) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243: 1731–1734PubMedCrossRefGoogle Scholar
  5. 5.
    Boucher CAB, O’Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, Lange JMA, Goudsmit J, Larder BA (1992) Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency viruspositiv subjects. J Infect Dis 165: 105–110PubMedCrossRefGoogle Scholar
  6. 6.
    Larder BA, Kellam P, Kemp SD (1991) Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 5: 137–144PubMedCrossRefGoogle Scholar
  7. 7.
    Coombs RW, Collier AC, Allain JP, Nikora B, Leuther M, Gjerset GF, Corey L (1989) Plasma viremia in human immunodeficiency virus infection. N Engl J Med 321: 1626–1631PubMedCrossRefGoogle Scholar
  8. 8.
    Shirasaka T, Yarchoan R, O’Brien MC, Husson RN, Anderson BD, Kojima E, Shimada T, Broder S, Mitsuya H (1993) Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine dideoxycytidine, and didesoxyinosine: an in vitro comparative study. Proc Natl Acad Sci USA 90: 562–566PubMedCrossRefGoogle Scholar
  9. 9.
    Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chainterminating inhibitors. Proc Natl Acad Sci USA 74: 5463–5467PubMedCrossRefGoogle Scholar
  10. 10.
    Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA (1992) Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256: 1 783–1790Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • A. von Brunn
  • J. Eberle
  • U. Notheis
  • G. Auberger
  • F. Rommel
  • W. Schramm
  • L. Bader
  • L. Gürtler

There are no affiliations available

Personalised recommendations